SENISCA Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 15

Employees

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $4.71M

  • Investors
  • 12

SENISCA General Information

Description

Developer of anti-aging oligonucleotide therapeutics designed to deliver effective pharmaceutical treatments for treating age-related chronic diseases. The company provides a new generation of oligonucleotide-based interventions to turn back the aging clock in old cells and to target the diseases and aesthetic signs of aging by restoring the ability of cells to fine-tune the expression of their genes, enabling people to live healthily for a longer period and rejuvenate aged cells.

Contact Information

Website
www.senisca.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • RILD Building
  • Barrack Road
  • Exeter EX2 5DW
  • England, United Kingdom
+44 07515
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • RILD Building
  • Barrack Road
  • Exeter EX2 5DW
  • England, United Kingdom
+44 07515

SENISCA Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SENISCA Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Seed Round 20-Feb-2024 $4.71M Completed Pre-Clinical Trials
9. Accelerator/Incubator 01-Dec-2023 Completed Pre-Clinical Trials
8. Grant 20-Apr-2023 Completed Pre-Clinical Trials
7. Seed Round 15-Feb-2022 Completed Pre-Clinical Trials
6. Grant Completed Pre-Clinical Trials
5. Grant 01-Jan-2022 Completed Pre-Clinical Trials
4. Seed Round 23-Feb-2021 Completed Pre-Clinical Trials
3. Accelerator/Incubator 01-Jan-2020 Completed Startup
2. Grant $96.5K Completed Startup
1. University Spin-Out 01-Jan-2020 Completed Startup
To view SENISCA’s complete valuation and funding history, request access »

SENISCA Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary 41,181 $0.001265 $38.7 $38.7 1x $38.7 18.95%
Ordinary 1,452 $0.001265 $34.83 $34.83 1x $34.83 0.67%
To view SENISCA’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

SENISCA Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of anti-aging oligonucleotide therapeutics designed to deliver effective pharmaceutical treatments for treatin
Drug Discovery
Exeter, United Kingdom
15 As of 2026

Cambridge, MA
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

SENISCA Competitors (1)

One of SENISCA’s competitors is Alnylam Pharmaceuticals (Royalties and Commercial Milestones for Inclisiran based in United States), a Private Equity-Backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alnylam Pharmaceuticals (Royalties and Commercial Milestones for Inclisiran based in United States) Private Equity-Backed Cambridge, MA
You’re viewing 1 of 1 competitors. Get the full list »

SENISCA Patents

SENISCA Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202508255-D0 Combination Pending 28-May-2025
GB-202508258-D0 Combination Pending 28-May-2025
GB-202508259-D0 Combination Pending 28-May-2025
GB-202508263-D0 Combination Pending 28-May-2025
GB-202508265-D0 Combination Pending 28-May-2025
To view SENISCA’s complete patent history, request access »

SENISCA Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SENISCA Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Exeter Innovation Accelerator/Incubator
APEX Ventures Venture Capital Minority
LifeSpan Vision Ventures Venture Capital Minority
QantX Venture Capital Minority
Innovate UK Government
You’re viewing 5 of 12 investors. Get the full list »

SENISCA FAQs

  • When was SENISCA founded?

    SENISCA was founded in 2020.

  • Where is SENISCA headquartered?

    SENISCA is headquartered in Exeter, United Kingdom.

  • What is the size of SENISCA?

    SENISCA has 15 total employees.

  • What industry is SENISCA in?

    SENISCA’s primary industry is Drug Discovery.

  • Is SENISCA a private or public company?

    SENISCA is a Private company.

  • What is the current valuation of SENISCA?

    The current valuation of SENISCA is .

  • What is SENISCA’s current revenue?

    The current revenue for SENISCA is .

  • How much funding has SENISCA raised over time?

    SENISCA has raised $10.7M.

  • Who are SENISCA’s investors?

    Exeter Innovation, APEX Ventures, LifeSpan Vision Ventures, QantX, and Innovate UK are 5 of 12 investors who have invested in SENISCA.

  • Who are SENISCA’s competitors?

    Alnylam Pharmaceuticals (Royalties and Commercial Milestones for Inclisiran based in United States) is a competitor of SENISCA.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process